ArticleCancer research2026

Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.

Sarah K Herzog et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.